MSTN and facioscapulohumeral muscular dystrophy: The role of DNA methylation and chromatin restructuring in FSHD also introduces the possibility that therapies that are being investigated in other epigenetic disorders will have utility in the treatment of FSHD.78 Clinical trials are being considered to determine the efficacy of several pharmacologic compounds—including selective androgen receptor modulators, myostatin inhibitors, and troponin activators—in the FSHD population.